Zynerba Pharmaceuticals, Inc.
(NASDAQ : ZYNE)

( )
ZYNE PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
HZNPHorizon Therapeutics Plc 2.57%58.766.5%$173.62m
CTLTCatalent, Inc. 3.40%76.242.1%$127.11m
VRXValeant Pharmaceuticals International, Inc. -4.83%17.5414.1%$103.21m
JAZZJazz Pharmaceuticals Plc -1.14%107.542.4%$96.91m
BHCBausch Health Cos., Inc. -4.83%17.540.0%$73.39m
UTHRUnited Therapeutics Corp. -0.69%117.7814.3%$69.53m
ICPTIntercept Pharmaceuticals, Inc. -2.91%44.0516.8%$60.95m
AXSMAxsome Therapeutics, Inc. 2.34%85.841.9%$53.99m
PCRXPacira Biosciences, Inc. 4.38%56.5410.3%$51.91m
ZGNXZogenix, Inc. 2.54%28.287.5%$49.40m
PRGOPerrigo Co. Plc -0.54%54.906.8%$48.11m
MYOKMyoKardia, Inc. 1.33%95.291.8%$46.96m
ARGXargenx SE 2.44%251.380.0%$42.46m
GWPHGW Pharmaceuticals Plc -0.48%129.006.2%$39.30m
AMRNAmarin Corp. Plc 0.45%6.771.6%$37.59m

Company Profile

Zynerba Pharmaceuticals, Inc. engages in the provision of pharmaceutically-produced transdermal cannabinoid therapies. It focuses on research and development of rare and near-rare neuropsychiatric conditions. It offers Zygel product which formulated as a permeation-enhanced gel for transdermal delivery. The company was founded by Audra L. Stinchcomb on January 31, 2007 and is headquartered in Devon, PA.